EU-collaborative projects at KI

During 2021, KI participated in 206 EU funded collaborative research-projects, of which 10 as the coordinating organisation. A large number our projects are funded through the EU health programmes, but our researchers also participate in projects within the programmes for future and emerging technologies, nanosciences, research infrastructures and communication technologies. In addition, KI contributes to projects within the joint-venture Innovative Medicines Initiative (IMI).

Latest news in this area

Projects within the H2020 Health, Demographic Change and Wellbeing Coronavirus Emergency Call


The project aims at developing a vaccine against the novel coronavirus SARS-CoV-2. 

Project name: OpenCorona
Project period: 1 Apr 2020 – 31 Mar 2022
Funding: EUR 3 million
Participants: 7 partners
Coordinators: Matti Sällberg and Gustaf Ahlén, Department of Laboratory Medicine
Project webpage


The goal of the project is to produce antibodies that block the ability of the virus to infect cells, so-called neutralising antibodies.

Project name: CoroNAb
Project period: 1 Apr 2020 – 31 Mar 2022
Funding: EUR 2,8 million 
4 partners
CoordinatorsBenjamin Murrell, Gerald McInerney and Gunilla Karlsson Hedestam, Department of Microbiology, Tumor and Cell Biology
Feature article about the project

Antibody Therapy Against Coronavirus

With this project the researchers want to develop passive immunotherapy against SARS-CoV-2 with the help of donated blood samples from recovered COVID-19 patients.

Project name: Antibody Therapy Against Coronavirus
Project period: 1 Apr 2020 – 31 Mar 2022
Funding: EUR 3 million
Participants: 5 partners
Coordinators: Qiang Pan Hammarström, Department of Biosciences and Nutrition, and Harold Marcotte and Lennart Hammarström, Department of Laboratory Medicine
News article about the award

Ongoing KI-coordinated H2020 Health, Demographic Change and Wellbeing projects


Action Leveraging Evidence to Reduce perinatal morTality and morbidity in sub-Saharan Africa

Project name: ALERT
Call: H2020-SC1-BHC-2018-2020
Project period: 1 Jan 2020 – 31 Dec 2024
Funding: EUR 4 million
Participants: 8 partners
Coordinator: Claudia Hanson, Department of Global Public Health (GPH)


Molecular atlas of the brain across the human lifespan

Project name: BRAINTIME
Call: H2020-SC1-BHC-2018-2020 
Project period: 1 Jan 2020 – 31 Dec 2021
Funding: EUR 4.4 million
Participants: 5 partners
Coordinator: Sten Linnarsson, Department of Medical Biochemistry and Biophysics (MBB)


Human Exposome Assessment Platform

Project name: HEAP
Call: H2020-SC1-BHC-2018-2020 
Project period: 1 Jan 2020 – 31 Dec 2024
Funding: EUR 12 million
Participants: 12 partners
Coordinator: Joakim Dillner, Department of Laboratory Medicine (LABMED)
News story about all new EU projects at KI in 2019


Novel testing strategies for endocrine disruptors in the context of developmental neurotoxicity.

Project name: ENDpoiNTs
Call: H2020-SC1-BHC-2018-2020
Project period: 1 January 2019 – 31 December 2023
Funding: EUR 6.9 million
Participants: 16 partners
Coordinator: Joelle Rüeg, Institute of Environmental Medicine (IMM)


Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalised medicine.

Project name: MultipleMS
Call: H2020-SC1-2016-RTD
Project period: 1 January 2017 – 31 December 2021
Project funding: EUR 14.7 million
Participants: 21 partners
Coordinator: Ingrid Kockum, Department of Clinical Neuroscience
More on the project website
About this project in the database of the European Commission


Stem cell therapy before birth against brittle bones disease.

Project name: Boost Brittle Bones Before Birth (BOOSTB4)
Call: H2020-PHC-2015-single-stage-RTD
Project period: 1 January 2016 – 31 December 2020
Participants: 12 partners
Coordinator: Cecilia Götherström, Department of Clinical Science, Intervention and Technology
More about BOOSTB4 on the project website
Read a news article about the upstart of this project


Precision medicine in overlapping psychiatric disorders. The goal of this research project is to find an effective therapy for rare individuals with synaptic mutations causal to intellectual disability, autism, and/or schizophrenia.

Project name: Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders (COSYN)
Call: H2020-PHC-2015-two-stage
Project period: 1 January 2016 – 31 December 2020
Participants: 14 partners
Coordinator: Patrick Sullivan, Department of Medical Epidemiology and Biostatistics
More on the website of COSYN


Secure chemicals for future generations. Integrating epidemiology and experimental biology to improve risk assessment of exposure to mixtures of endocrine disruptive compounds.

Project name: EDC-MixRisk
Call: H2020-PHC-2015-single-stage-RTD
Project period: 1 May – 30 April 2019
Funding: EUR 6.2 million
Participants: 12 partners
Coordinator: Åke Bergman, Swetox
More about EDC-MixRisk on the project website


The aim of SMART2D is to strengthen capacity for type 2 diabetes prevention and management through task-shifting among health care providers and community health workers, and expanding care networks through community-based peer support groups, by targeting three populations in different settings.

Project name: Self management approach and reciprocal transfer for type 2 diabetes (SMART2D)
Call: Horizon 2020 Health – Research and innovation action (RIA)
Project period: 2 January 2015 – 31 March 2019 (51 months)
Participants: 6 partners
Coordinator: Meena Daivadanam, Department of Global Public Health
More on the SMART2D project website
KI News: "Sharing of knowledge from an international project on how to manage your type-2 diabetes"

Ongoing KI-coordinated projects within IMI

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.


Prevent and treat Rheumatoid Arthritis through immune tolerising therapies.

Project name: Rheuma Tolerance for Cure (RTCure)
Project period: 1 September 2017 – 31 August 2022
EU funding: EUR 6 million
Participants: 20 partners
Coordinator: Lars Klareskog, Department of Medicine, Solna
More about the project on the EU website

Ongoing KI-coordinated projects within Future and Emerging Technologies (FET)


Project name: Next generation precision antibody profiling - from science fiction to reality
Call: H2020-FETOPEN-2018-2019-2020-01
Project period: 1 January 2019 – 31 December 2021
Participants: 8 partners
Coordinator: Roman Zubarev, Department of Medical Biochemistry and Biophysics

Ongoing KI-coordinated projects within EDCTP2

The EDCTP2 programme is funded by the EU Horizon 2020 through the European and Developing Countries Clinical Trials Partnership Association (EDCTP).


The development of systems for drugs safety in East Afrika. Co-funded by EDCTP2, the Swedish International Development Cooperation Agency, Karolinska Institutet, Pharmacy and Poisons Board (in Kenya), Muhimbili University of Helath and Allied Sciences (in Tanzania), and Tanzania Food and Drugs Authority.

Project name: Pharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa (PROFORMA)
Project period: 1 March 2018 – 28 February 2023 (60 months)
Funding: EUR 6 million
Participants: 10 partners
Coordinator: Eleni Aklillu, Department of Laboratory Medicine
More information at the project website
News article at KI News